GoAI
Get started
Wakamoto Pharmaceutical Co.,Ltd. logo

Wakamoto Pharmaceutical Co.,Ltd.

4512.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

¥306

+¥9.00 · +3.03%

Aug 24, 3:30 PM JST

4512.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Tomoyuki Hirai
Listed since
Jan 1, 2001
Employees
303

Market position

Volume
103.5K
1.62× average
Average volume
63.99K
Average daily volume
Market cap
10.62B JPY
Beta
0.47
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
10.58B JPY
P/E (TTM)
31.03×
P/B (TTM)
0.91×
P/S (TTM)
1.04×
EV / EBITDA
15.08×
Earnings yield
1.87%
Free cash flow yield
-8.63%
Dividend yield
1.14%

Profitability & efficiency

Gross margin
45.87%
Operating margin
2.58%
Net margin
3.37%
Return on equity
1.89%
Return on assets
1.38%
Return on invested capital
1.63%

Financial health

Debt / equity
0.03×
Current ratio
3.48×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends58%35%11%-12%Gross margin, FY2021: 51.96%Gross margin, FY2022: 47.44%Gross margin, FY2023: 45.76%Gross margin, FY2024: 46.50%Gross margin, FY2025: 47.75%Operating margin, FY2021: -0.16%Operating margin, FY2022: 1.63%Operating margin, FY2023: -2.53%Operating margin, FY2024: -5.88%Operating margin, FY2025: 2.58%Net margin, FY2021: 2.85%Net margin, FY2022: 1.60%Net margin, FY2023: 1.41%Net margin, FY2024: 0.83%Net margin, FY2025: 2.29%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 51.96%. Gross margin FY2022 47.44%. Gross margin FY2023 45.76%. Gross margin FY2024 46.50%. Gross margin FY2025 47.75%. Operating margin FY2021 -0.16%. Operating margin FY2022 1.63%. Operating margin FY2023 -2.53%. Operating margin FY2024 -5.88%. Operating margin FY2025 2.58%. Net margin FY2021 2.85%. Net margin FY2022 1.60%. Net margin FY2023 1.41%. Net margin FY2024 0.83%. Net margin FY2025 2.29%.

Income trends

Revenue

9.91B JPY+27.18%

Operating income

255.54M JPY+713.34M JPY

Net income

227.22M JPY+252.60%
Income trends across reported periods10.94B JPY6.8B JPY2.65B JPY−1.49B JPYRevenue, FY2021: 8.38B JPYRevenue, FY2022: 8.66B JPYRevenue, FY2023: 7.74B JPYRevenue, FY2024: 7.79B JPYRevenue, FY2025: 9.91B JPYOperating income, FY2021: −13.39M JPYOperating income, FY2022: 141.47M JPYOperating income, FY2023: −195.51M JPYOperating income, FY2024: −457.8M JPYOperating income, FY2025: 255.54M JPYNet income, FY2021: 238.54M JPYNet income, FY2022: 138.26M JPYNet income, FY2023: 108.96M JPYNet income, FY2024: 64.44M JPYNet income, FY2025: 227.22M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 8.38B JPY. Revenue FY2022 8.66B JPY. Revenue FY2023 7.74B JPY. Revenue FY2024 7.79B JPY. Revenue FY2025 9.91B JPY. Operating income FY2021 −13.39M JPY. Operating income FY2022 141.47M JPY. Operating income FY2023 −195.51M JPY. Operating income FY2024 −457.8M JPY. Operating income FY2025 255.54M JPY. Net income FY2021 238.54M JPY. Net income FY2022 138.26M JPY. Net income FY2023 108.96M JPY. Net income FY2024 64.44M JPY. Net income FY2025 227.22M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue9.91B JPY7.79B JPY7.74B JPY8.66B JPY8.38B JPY
Cost of goods sold5.18B JPY4.17B JPY4.2B JPY4.55B JPY4.03B JPY
Gross profit4.73B JPY3.62B JPY3.54B JPY4.11B JPY4.36B JPY
Research and development—419.08M JPY513.31M JPY580.45M JPY593.96M JPY
Selling, general, and administrative4.47B JPY4.08B JPY3.22B JPY3.33B JPY3.78B JPY
Operating expenses4.47B JPY4.08B JPY3.74B JPY3.97B JPY4.37B JPY
Interest income2.59M JPY1.43M JPY29K JPY28K JPY25K JPY
Interest expense1.9M JPY882K JPY531K JPY578K JPY575K JPY
Depreciation and amortization442.93M JPY430.34M JPY345.46M JPY363.65M JPY470.08M JPY
Operating income255.54M JPY−457.8M JPY−195.51M JPY141.47M JPY−13.39M JPY
Net income227.22M JPY64.44M JPY108.96M JPY138.26M JPY238.54M JPY

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy00%
Buy436%
Hold655%
Sell19%
Strong sell00%

4512.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4512.T

research.disclaimer